Dupilumab treatment of eosinophilic gastrointestinal disease in an adolescent

Pediatr Allergy Immunol. 2023 Jun;34(6):e13973. doi: 10.1111/pai.13973.

Authors

Francesca Mori¹, Sara Renzo², Simona Barni¹, Luca Scarallo^{2

3}, Mattia Giovannini^{1

4}, Vincenzo Villanacci⁵, Paolo Lionetti^{2

3}

Affiliations

¹ Allergy Unit, Meyer Children's Hospital, IRCCS, Florence, Italy.
² Gastroenterology and Nutrition Unit, Meyer Children's Hospital, IRCCS, Florence, Italy.
³ Department of NEUROFARBA, University of Florence, Florence, Italy.
⁴ Department of Health Sciences, University of Florence, Florence, Italy.
⁵ Institute of Pathology ASST-Spedali Civili, Brescia, Italy.

PMID: 37366213
DOI: 10.1111/pai.13973

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Antibodies, Monoclonal, Humanized / therapeutic use
Enteritis* / drug therapy
Eosinophilia* / drug therapy
Humans

Substances

dupilumab
Antibodies, Monoclonal, Humanized

Supplementary concepts

Eosinophilic enteropathy